CMPS
MaterialsCompass Pathways Plc
$9.76+0.44 (+4.72%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CMPS Today?
No stock-specific AI insight has been generated for CMPS yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding134.9M
CMPS News
22 articles- Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026Yahoo Finance·May 6, 2026
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 6, 2026
- Neuronetics Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Does FDA’s Rolling Review Of COMP360 Psilocybin Depression Therapy Change The Bull Case For COMPASS Pathways (CMPS)?Yahoo Finance·May 4, 2026
- Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Airbnb, Alphabet, Check Point Software, GlobalFoundries, International Paper, Trade Desk, and More247 Wall St·May 4, 2026
- Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?Barchart·Apr 28, 2026
- Error: Response status code does not indicate success: 503 (Service Unavailable).Marketbeat·Apr 27, 2026
- These 3 Psychedelic Stocks Activated After Trump’s Executive OrderInvesting.com·Apr 27, 2026
- These 3 Psychedelic Stocks Activated After Trump's Executive OrderMarketbeat·Apr 27, 2026
- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·Apr 27, 2026
- FDA Grants Rolling Review and CNPV Designation to Compass Pathways (CMPS) for TRD TreatmentYahoo Finance·Apr 27, 2026
- FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.Yahoo Finance·Apr 24, 2026
- Sector Update: Health Care Stocks Fall Late AfternoonYahoo Finance·Apr 24, 2026
- Sector Update: Health Care Stocks Decline in Afternoon TradingYahoo Finance·Apr 24, 2026
- A Look At COMPASS Pathways (CMPS) Valuation After Regulatory Shift And Phase 3 Psilocybin ResultsYahoo Finance·Apr 24, 2026
- Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check.Yahoo Finance·Apr 24, 2026
- Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority VoucherYahoo Finance·Apr 24, 2026
- FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers GainYahoo Finance·Apr 24, 2026
- Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?Yahoo Finance·Apr 24, 2026
- What Makes COMPASS Pathways PLC Sponsored ADR (CMPS) a Strong Momentum Stock: Buy Now?Yahoo Finance·Apr 22, 2026
- How Much Upside is Left in COMPASS Pathways (CMPS)? Wall Street Analysts Think 136%Yahoo Finance·Apr 22, 2026
- The Psychedelic Revolution in Mental HealthcareThe Motley Fool·Apr 17, 2026
All 22 articles loaded
Price Data
Open$9.45
Previous Close$9.32
Day High$9.80
Day Low$9.16
52 Week High—
52 Week Low—
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding134.9M
About Compass Pathways Plc
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—